Conclusion: The evidence produced by this systematic review does not support
In the landmark Second National Spinal Cord Injury Study (NASCIS-II), 437 participants with acute TSCIs were randomized to an initial bolus of 30 mg/kg of
Patients were
Spinal cord injury has become epidemic in modern society
While no definitive medical treatment exists, the role of methylprednisolone (MP) in the management of ASCI and other spinal cord pathologies has been investigated in depth; however, its use remains
et al
High doses of methylprednisolone (MPSS) came into use as part of a therapeutic protocol for acute spinal cord injuries following the published results from the NASCIS II study in 1992; they soon became a standard of care around the world
Due to the continuing debates on the utility of high-dose methylprednisolone (MP) early after acute spinal cord injury (ASCI), we aimed to evaluate the therapeutic and adverse effects of high-dose MP according to the second National Acute Spinal Cord Injury Study (NASCIS-2) dosing protocol in comparison to
Methylprednisolone (Solu-Medrol), given through a vein in the arm, has been used as a treatment option after a spinal cord injury in the past
10
Methylprednisolone is an FDA-approved medication for the management and treatment of allergic conditions, arthritis, asthma exacerbations, long-term asthma maintenance, acute exacerbation of multiple sclerosis, and as an anti-inflammatory and immunosuppressive agent
Systemic administration of a high-dose of Methylprednisolone (MP) can reduce neurological deficits after acute spinal cord injury (SCI)
Systemic administration of a high-dose of Methylprednisolone (MP) can reduce neurological deficits after acute spinal cord injury (SCI)
Journal Club: High-dose methylprednisolone for acute traumatic spinal cord injury: A meta-analysis Neurology